News & Updates

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

Children with hypertension, particularly those with primary hypertension, are vulnerable to developing metabolic syndrome (MetS), reveals a study.

The PINNACLE-I trial shows the feasibility, safety, and efficacy of LithiX, a novel Hertz contact intravascular lithotripsy (HC-IVL) device, for the treatment of calcified coronary artery lesions.

Both the Dietary Approaches to Stop Hypertension (DASH) diet and sodium intake reduction are effective in lowering absolute blood pressure (BP) levels, but these interventions do not yield significant benefits in BP variability (BPV), reports a study.

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

A traditional Chinese qigong exercise, Baduanjin, has been shown in a recent study to reduce systolic blood pressure (SBP) after 3 months of intervention in people with high-normal BP.